2023 International Congress » Parkinson's Disease: Molecular Mechanisms of Disease

Meeting: 2023 International Congress

A novel, population-specific PINK1 p.F385S loss of function mutation in an Indian family with Parkinson’s disease

K. Sharma, A. Kishore, A. Lechado, F. Raimondi, M. Sturm, A. Ashok-Kumar-Sreelatha, D. Kalikavil-Puthenveedu, G. Sarma, N. Casadei, R. Krüger, T. Gasser, P. Kahle, O. Riess, J. Fitzgerald, M. Sharma (Tübingen, Germany)

Are GDNF receptors the gatekeepers of GDNF efficacy during progressive nigrostriatal neuron loss?

M. Salvatore, E. Kasanga, Y. Han, R. Mcmanus, W. Navarrete, V. Nejtek, J. Richardson (Fort Worth, USA)

Blood derived α-synuclein seeding in the course of Parkinson’s Disease

A. Kluge, E. Schaeffer, K. Brockmann, C. Schulte, C. Deuschle, J. Bunk, W. Maetzler, D. Berg (Kiel, Germany)

Characterization of the pathogenic α-Synuclein variant p.V15A in Parkinson´s disease

S H. Diaw, F. Buratti, L. Streubel-Gallasch, M. Borsche, M. Dulovic-Mahlow, C O. Fernández, J. Seeliger, I. Lenz, P. Seibler, C. Klein, N. Brüggemann, M. Zweckstetter, M. Vos, K. Lohmann (Lübeck, Germany)

Cholinergic deficits in Parkinson Disease

R. Miller, D. Dhavale, J. O’Shea, E. Franklin, N. Cairns, R. Perrin, M. Campbell, J. Perlmutter, P. Kotzbauer (St. Louis, USA)

Comparative whole transcriptome analysis of human and mice models of Parkinson’s disease bearing defective glucocerebrosidase activity revealed alteration of expression profile of genes involved in the autophagy

A. Bezrukova, K. Basharova, M. Rudenok, M. Nikolaev, A. Kopytova, I. Miliukhina, A. Emelyanov, M. Shadrina, P. Slominsky, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

Correlation of clinical profile of Parkinsonism with molecular imaging

S. Lavania, A. Pattojoshi, AH. Khan (Agra, India)

Country and Sex Differences in Diagnosis Latency of Parkinson’s Disease in Latin American Populations

J. Ramchandra, M. Inca-Martinez, TP. Leal, E. Gatto, F. Micheli, BL. Santos-Lobato, F. Cardoso, G. Letro, P. Braga-Neto, V. Peixoto, AF. Schumacher-Schuh, C. Rieder, V. Tumas, V. Borges, P. Chana, P. Saffie, P. Olguin, A. Colombo, JL. Orozco Vélez, C. Velez-Pardo, M. Del Rio, A. Medina, M. Rodriguez-Violante, AJ. Hernandez-Medrano, D. Martinez-Ramirez, A. Ruiz-Contreras, A. Lazaro-Figueroa, P. Reyes, M. Cornejo-Olivas, AC. Medina Colque, JE. Rios Pinto, A. Viñuela, IF. Mata (Cleveland, USA)

Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia

E. Kim, J. Shaqfah, I. Frouni, P. Huot (Montreal, Canada)

Differential Rab10 & Rab8A phosphorylation by LRRK2 variants G2019S & I1371V manifests differences in membrane fluidity & pathogenicity.

KH. Singh, IND. Datta (Bengaluru, India)

Distinct temporal and spatial alteration of immunoproteasome in Parkinson’s Disease pathogenesis

HD. Nguyen, YE. Kim, TT. Lai, HN. Pham, IH. Kwak, H. Ma (Anyang, Gyeonggi-do, Republic of Korea)

Estrogen derivatives and hydrogen peroxide as promising biomarkers in parkinson’s disease-preliminary results

J. Sławek, P. Bastian, A. Roszmann, J. Dulski, D. Jacewicz, J. Drzezdzon, A. Kuban-Jankowska, M. Wozniak, N. Knap, T. Bączek, L. Konieczna, M. Belka, M. Gorska-Ponikowska (Gdańsk, Poland)

Exploring mitochondrial mechanisms defining Parkinson’s disease penetrance in LRRK2 G2019S neuronal cultures

S. Delcambre, J. Ghelfi, S. Hezzaz, C. Klein, J. Trinh, P. Seibler, P. Antony, S. Pereira, A. Grünewald (Esch-sur-Alzette, Luxembourg)

Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease

S. Chatterjee, H. Thakkar, A. Khairnar, R. Shah (Gandhinagar, India)

Hypoxia‑induced astrocyte activation and its protective effect on Parkinson’s disease

M. Kim, S-H. Kim, HN. Choi, JY. Je, SP. Yun (Jinju, Republic of Korea)

Identification of reproducible metabolites for Parkinson’s Disease diagnosis using clinical data and computational modelling

X. Luo, YJ. Liu, A. Balck, C. Klein, R. Fleming (Galway, Ireland)

Impaired CaMKII/ERK activation in mouse mutant LRRK2 R1441G fibroblasts was associated with reduced mitochondrial calcium store and efflux in response to depolarization stress

E. Chang, Y. Malki, Z. Choi, H. Liu, S. Zhang, S. Pang, M. Kung, D. Ramsden, S. Ho, P. Ho (Hong Kong, Hong Kong)

Impaired lysophagy function exacerbates propagation of α-synuclein aggregation

K. Kakuda, K. Ikenaka, C. Aguirre, C. Choong, J. Doi, Y. Kimura, H. Mochizuki (Osaka, Japan)

Impaired mitochondrial respiration as a peripheral tissue biomarker for stratifying idiopathic Parkinson’s disease

S. Kverneng, K. Stige, H. Berven, S. Mostafavi, M. Brischigliaro, B. Brakedal, G. Skeie, G. Nido, I. Flønes, E. Fernandez-Vizarra, C. Dölle, C. Tzoulis (Bergen, Norway)

Impaired Mitophagy and Mitochondrial-energetics in Parkinson’s disease: A Novel Therapeutic Strategy of Re-tasking Felodipine

A. Roy, S. Choudhury, R. Banerjee, A. Costa, P. Sheshadri, M. Duchen, S. Dey, H. Kumar (Kolkata, India)

Impairment of SHH signaling in PD LRRK2 I1371V iPSC derived floor plate cells contribute to ontogenic origin of lower dopaminergic-neuron yield

I. Datta, S. Jagtap, C. Potdar, K. Singh (Bengaluru, India)

Inhibition of LRRK2 kinase activity promotes glucocerebrosidase transport to the lysosomes in primary monocyte-derived macrophages from patients with GBA-associated Parkinson’s disease

K. Basharova, A. Bezrukova, A. Izyumchenko, G. Baydakova, I. Miliukhina, E. Zakharova, S. Pchelina, T. Usenko (Gatchina, Russian Federation)

Investigating glutamate toxicity associated to Park2 mutations in pre-clinical models of Parkinson’s Disease

I. Trezzi, M. Regoni, M. Magni, M. Schröter, A. Buccino, D. Lopez, G. Faustini, L. Murro, F. Biella, E. Frattini, R. Silipigni, M. Passafaro, A. Bellucci, M. Bortolozzi, J. Sassone, A. Di Fonzo (Milan, Italy)

Isolation of L1CAM-extracellular vesicles reveals signs of insulin resistance in Parkinson’s disease

I. Markaki, W. Paslawski, T. Ntetsika, P. Svenningsson (Stockholm, Sweden)

Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease

R. Miller, A. Li, M. Campbel, J. Perlmutter, P. Kotzbauer (St. Louis, USA)

LRRK2 G2019S as a trigger of inflammatory signaling in patient-derived microglia

K. Badanjak, P. Mulica, M. Tziortziou, S. Delcambre, S. Smajic, C. Venegas, M. Ali, T. Rolova, J. Koistinaho, P. Seibler, S. Cowley, J. Trinh, S. Pereira, P. Antony, E. Glaab, A. Grünewald (Esch-sur-Alzette, Luxembourg)

LRRK2 G2019S promotes astrocytic inflammatory response induced by oligomeric α-synuclein through NF-κB pathway

JY. Liu, KJ. He, JB. Zhang, F. Wang, CF. Liu (Suzhou, China)

Lysosomal-driven reduction of alpha-synuclein aggregates in a neuron-like model of Parkinson’s disease

S. Lucas-Del-Pozo, G. Uras, F. Fierli, AHV. Schapira (London, United Kingdom)

Membrane-associated properties and ER stress alterations in LRRK2 I1371V patient iPSC derived neurons increase susceptibility to oxidative stress.

S. Jagtap, I. Datta (Bengaluru, India)

Metabolic modulation of mitochondrial DNA release in cellular models of Parkin-associated Parkinson’s disease

G. Agyeah, P. Antony, K. Wasner, A. Rakovic, S. Pereira, A. Grünewald (Esch-Sur-Alzette, Luxembourg)

miRNAs from blood serum as an early diagnostic biomarker for Parkinson’s disease: A study in an animal model

MD. Ahmad, PSD. Dholaniya (Hyderabad, India)

Modulation of autophagy and neuroinflammation by Niclosamide in MPTP Induced- Parkinson’s disease model

SHI. Kartik (Lucknow, India)

Neuroprotective effects of oral consumption of Bifidobacterium lactis and Lactobacillus acidophilus probiotics on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropytide-induced Parkinson’s Disease mouse model

C. Mo, Y. Qian, Y. Zhang, X. He, Y. Lai, S. Xu, P. Ai, X. Yang, Q. Xiao (Shanghai, China)

Non-invasive Vagus Nerve Stimulation Alters Molecular Markers in Parkinson’s Disease Patients with Freezing of Gait

R. Banerjee, B. Mondal, S. Choudhury, A. Roy, K. Chatterjee, P. Basu, S. Baker, M. Baker, H. Kumar (Kolkata, India)

Novel modifiers of heterozygous pathogenic Parkin variant penetrance in Parkinson’s disease

A. Hach, Z. Landoulsi, B. Meier, P. Seibler, C. Klein, P. May, A. Rakovic (Luebeck, Germany)

Olfactory neurons’ Substance P is highly expressed in Parkinson’s disease reflecting gastrointestinal dysfunction

T. Schirinzi, D. Maftei, P. Grillo, R. Bovenzi, J. Bissacco, C. Simonetta, H. Zenuni, FM. Passali, S. Di Girolamo, A. Stefani, NB. Mercuri, R. Lattanzi, C. Severini (Rome, Italy)

Parkin Coregulates Glutathione Metabolism in Adult Brain to Contribute to Redox Homeostasis

D. El Kodsi, J. Tokarew, R. Sengupta, A. Chatterji, M. Takanashi, N. Hattori, J. Tomlinson (Ottawa, Canada)

Premenstrual worsening of UPDRS motor scale in women affected by Parkinson’s Disease

A. Thomas, D. Calisi, M. de Rosa, P. Ajdinaj, S. Sensi, M. Onodrj (Chieti, Italy)

Protein X: a key player in Parkinson’s Disease pathophysiology? – insights from compound screening in gba1 knock-out medaka

E. Nakanishi, T. Taguchi, N. Uemura, H. Yamakado, R. Takahashi (Kyoto, Japan)

Proteomic profiles analysis of plasma exosomes and WBC reveals news insights of PD patients classified into H&Y clinical stage

BL. Fadel, N. Woldmar, G. Poralla, J. Fontes, L. Giacomin, M. Figueiredo, J. Evaristo, F. Nogueira, C. Panis, A. Rosso, L. Pizzatti (Rio de Janeiro, Brazil)

RNA editing contributes to the inflammatory astrocytic response in Parkinson’s disease.

A. Wagen, K. D'Sa, M. Choi, S. Strohbuecker, G. Young, R. Reynolds, S. Garcia-Ruiz, Z. Chen, A. Ghareeb, J. Bayne, S. Rodriques, M. Horrocks, S. Gandhi, M. Ryten (London, United Kingdom)

SARS-CoV-2 infection exacerbates the cellular pathology in Parkinson’s disease progression

HN. Choi, BN. Lee, YH. Che, MG. Ko, HM. Seong, MG. Jo, KS. Lyoo, YJ. Kim, SP. Yun (Jin-Ju, Republic of Korea)

Selegiline drives autophagic secretion of α-synuclein

Y. Nakamura, S. Arawaka (Takatsuki, Japan)

Selenium mitigates ferroptosis-mediated dopaminergic cell death by regulating the Nrf2/GPX4 pathway: Implication for Parkinson’s disease

YJ. Jung, H. Choi, E. Oh (Daejeon, Republic of Korea)

SLP-2 modulated expression rescues mitochondrial function in alpha-synuclein neuropathology models

M. Castelo, G. Gentile, A. Zanon, A. Lavdas, C. Bolduc, M. Picon, S. Laouafa, J. Soliz, M. Lévesque, I. Pichler (Bolzano, Italy)

Small Molecule Inhibitors for Precise Inhibition of α-Synuclein Oligomer Generation in Parkinson’s Disease (PD)

A. Cridland, S. Ball, X. Teng, M. Castellana Cruz, K. Pisani, J. Olano Bringas, P. Villegas, I. Kitchen-Smith, X. Yang, B. Mannini, N. Bengoa-Vergniory, S. Brewerton, B. Li, R. Sivasankaran, J. Popovici-Muller, A. Plowright, J. Thomson, J. Habchi (Cambridge, United Kingdom)

Sub-cellular alterations in MPTP-induced in-vivo and in-vitro systems and Non-MPTP human Parkinsonian skin biopsies: Verifying the sequelae of differential toxicity

P. Alladi, B. Bhaduri, S. Rashmi, I. Datta, P. Pal, D. Srinivas, R. Yadav (Bangalore, India)

Synaptic density and α-synuclein oligomers in skin biopsies: differences between idiopathic and GBA-linked Parkinson’s disease

E. Contaldi, S. Mazzetti, M. Basellini, V. Ferri, E. Cereda, I. Isaias, G. Pezzoli, G. Cappelletti (Milan, Italy)

The Role of Adaptive Immunity caused by α-synuclein Recognition Specific Sequence Peptide on the Onset of Parkinson’s Disease Pathogenesis

MG. Jo, BN. Lee, HM. Seong, SH. Kim, HN. Choi, MG. Kim, SP. Yun (Jinju, Republic of Korea)

TREM2 maintain microglial proliferation and α-syn accumulation in PD models via the PI3K-Akt pathway

S. Yin, Y. Xia, F. Wan, L. Kou, T. Wang (Wuhan, China)

« View all sessions from the 2023 International Congress.